Paliperidone extended-release: A review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 15, 2010, Pages 2557-2567

  Canuso, Carla M ^a   Battisti, Wendy P ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Atypical antipsychotic; Bipolar disorder; Paliperidone; Psychiatry; Schizoaffective disorder; Schizophrenia

Indexed keywords

PALIPERIDONE;

BIPOLAR MANIA; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; UNITED STATES;

ANIMALS; BIPOLAR DISORDER; DELAYED-ACTION PREPARATIONS; HUMANS; ISOXAZOLES; PSYCHOTIC DISORDERS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 77957099824     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.495387     Document Type: Review

References (68)

1. Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord 2005;7(Suppl 4):21-33
2. Spier SA. Use of atypical antipsychotics: observations from clinical practice. J Clin Psychiatry 2006;67:490-491
3. Mohamed S, Leslie DL, Rosenheck RA. Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of veterans affairs. J Clin Psychiatry 2009;70:906-912
4. Collaborative Working Group on Clinical Trial Evaluations. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. J Clin Psychiatry 1998;59(Suppl 12):41-45
5. Masan PS. Atypical antipsychotics in the treatment of affective symptoms: a review. Ann Clin Psychiatry 2004;16:3-13
6. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1159-1172
7. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004;3:353-359
8. Seemuller F, Forsthoff A, Dittmann S, et al. The safety and tolerability of atypical antipsychotics in bipolar disorder. Expert Opin Drug Saf 2005;4:849-868
9. Edwards SJ, Smith CJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Clin Ther 2009;31:1345-1359
10. Kane JM, Fleischhacker WW, Hansen L, et al. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 2009;70:627-643
11. Correll CU. Multiple antipsychotic use associated with metabolic and cardiovascular adverse events in children and adolescents. Evid Based Ment Health 2009;12:93
12. Sikich L. Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders. J Clin Psychiatry 2008;69(Suppl 4):21-25
13. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93:117-130 (Pubitemid 46817944)
14. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-161
15. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007;62:1363-1370
16. Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry 2008;16:31-43
17. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharm 2007;27:6-14
18. Janssen LPJ, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.,. Invega (R), paliperidone extended-release prescribing information. Titusville, NJ 2010 (revised)
19. Boom S, Talluri K, Janssens L, et al. Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Pharmacol 2009;49:1318-1330
20. Karlsson P, Dencker E, Mannaert E, et al. Pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone extended-release in healthy subjects. Schizophr Res 2006;81(Suppl 1):85-86
21. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006;22:1879-1892
22. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124:57-73
23. Leysen JE, Janssen PM, Schotte A, et al. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl) 1993;112(1 Suppl):S40-54
24. Rossenu S, Mannaert E, Hargarter L, et al. D2-Receptor occupancies and corresponding plasma concentrations: a comparison of paliperidone extended-release (ER) with risperidone immediate-release (IR). 26th Symposium of the Working Group for Neuropsychopharmacology and Pharmacopsychiatry (AGNP - Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie) 7 - 10 October 2009;42:Munich, Germany. Pharmacopsychiatry 2009;42:238
25. Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008;36:769-779
26. Berwaerts J, Cleton A, Herben V, et al. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry 2009;42:158-163
27. Boom S, Thyssen A, Crauwels H, et al. The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int J Clin Pharmacol Ther 2009;47:606-616
28. Paulzen M, Orfanos S, Grunder G. Remission of drug-induced hepatitis after switching from risperidone to paliperidone. Am J Psychiatry 2010;167:351-352
29. Thyssen A, Cleton A, Talluri K, et al. No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Hum Psychopharmacol 2009;24:532-539
30. Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, et al. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry 2010;71(5):587-598
31. Canuso C, Schooler N, Carothers J, et al. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. J Clin Psychopharmacol 2010;30(5):487-495
32. Berwaerts J, Lane R, Nuamah I, et al. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord 2010. In press
33. Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000;101:323-329
34. Canuso CM, Bossie CA, Turkoz I, Alphs L. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms. Schizophr Res 2009;113:56-64
35. Canuso CM, Turkoz I, Sheehan JJ, Bossie CA. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms. J Affect Disord 2009;120:193-199
36. Luthringer R, Staner L, Noel N, et al. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 2007;22:299-308
37. Canuso CM, Dirks B, Carothers J, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2009;166:691-701
38. Grinspan A, Canuso CM, Merriman U, et al. Medication satisfaction in subjects with schizophrenia treated with paliperidone ER after suboptimal response to oral risperidone. 49th Annual New Clinical Drug Evaluation Unit Meeting; 29 June - 2 July 2009, Hollywood, FL, USA
39. Canuso CM, Youssef EA, Bossie CA, et al. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol 2008;23:209-215
40. Turkoz I, Bossie CA, Lindenmayer JP, et al. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. BMC Psychiatry, submitted
41. Cleton A, Rossenu S, Talluri K, et al. Evaluation of the pharmacokinetics of an extended-release formulation of paliperidone and an immediate-relase formulation of risperidone. Clin Pharmacol Ther 2007;83:S62
42. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, DSM-IV. American Psychiatric Press, Washington, D.C.; 1994
43. Cheniaux E, Landeira-Fernandez J, Lessa Telles L, et al. Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affect Disord 2008;106:209-217
44. Potkin SG, Alphs L, Hsu C, et al. Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. Biol Psychiatry 2003;54:444-452
45. Berwaerts J, Xu H, Nuamah I, et al. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study. J Affect Disord 2010 July 10. [Epub ahead of print]
46. Vieta E, Nuamah IF, Lim P, et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 2010;12:230-243
47. Johnson & Johnson Pharmaceutical Research & Development, LLC. A study to evaluate the effectiveness and safety of extended-release (ER) paliperidone compared with placebo in delaying the recurrence of symptoms in bipolar I disorder. Available from: www.clinicaltrials.gov/NCT00490971 [Last accessed 8 June 2010].
48. Amatniek J, Mao L, Rodriguez S, et al. Single-arm evaluation of paliperidone extedned-release (ER) in subjects with schizophrenia or schizoaffective disorder and haptic disease. Annual US Psychiatric and Mental Health Congress; 2 - 5 November 2009; Las Vegas, NV, USA.
49. Emsley R, Berwaerts J, Eerdekens M, et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008;23:343-356
50. Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol 2006;21:529-532
51. Knegtering R, Baselmans P, Castelein S, et al. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005;162:1010-1012
52. Pandina GJ, Canuso CM, Youssef E, et al. Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia. Hum Psychopharmacol 2007;22:326-7; author reply 8
53. Pani L, Marchese G. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. Expert Opin Drug Deliv 2009;6:319-331
54. Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 2009;29:64-73
55. Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008;69:817-829
56. Kane JM, Barrett EJ, Casey DE, et al. Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry 2004;65:1447-1455
57. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004;24(5 Suppl 1):S7-14
58. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-1773
59. Ritchie CW, Chiu E, Harrigan S, et al. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatry 2003;18:432-440
60. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160:1396-1404
61. Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006;67:509-516
62. Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry 2007;7:40
63. Perlis RH. Treatment of bipolar disorder: the evolving role of atypical antipsychotics. Am J Manag Care 2007;13(7 Suppl):S178-88
64. Letmaier M, Schreinzer D, Reinfried L, et al. Typical neuroleptics vs. atypical antipsychotics in the treatment of acute mania in a natural setting. Int J Neuropsychopharmacol 2006;9:529-537
65. Fuller BE, Rodriguez VL, Linke A, et al. Prevalence of liver diseases in veterans with bipolar disorder or schizophrenia. American Psychiatric Association 162nd Annual Meeting; 16 - 21 May 2009; San Francisco, CA, USA
66. Carney CP, Jones LE. Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. Psychosom Med 2006;68:684-691
67. Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J Gen Intern Med 2006;21:1133-1137 (Pubitemid 44506864)
68. Cournos F, McKinnon K, Sullivan G. Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus. J Clin Psychiatry 2005;66(Suppl 6):27-33